Williamsville, NY, United States of America

Takemasa Tsuji

This inventor holds 15 USPTO granted patents and 10 published patent applications, plus 3 CIPO patents and 4 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Agenus Inc., Ludwig Institute for Cancer Research Limited, Memorial Sloan Kettering Cancer Center. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takemasa Tsuji. Retrieved from https://idiyas.com/inventor/takemasa-tsuji

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 10)

% Patents Active = 93.3

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 4 (Patent Applications = 11)

Average Co-Inventor Count = 5.3

ph-index = 4

Forward Citations = 50(Granted Patents)

Location History:

Williamsville, NY (US) (2018 - 2022)
Buffalo, NY (US) (2019 - 2024)

Company Filing History:

Ludwig Institute for Cancer Research Limited

patents

9 out of 625

Memorial Sloan Kettering Cancer Center

patents

4. 6 out of 315

Health Research, Inc.

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

Areas of Expertise:

T Cell Receptors

Cancer Vaccines

Anti-GITR Antibodies

Tumor Antigen Recognition

Immune Response

Recombinant Proteins

Cloning Techniques

Antibody Therapy

Immunological Methods

Cancer Treatment

Therapeutic Compositions

Integrated Immune Responses

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12773445 - MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II-EXPRESSING CANCER CELL VACCINE AND METHODS OF USE FOR PRODUCING INTEGRATED IMMUNE RESPONSES (2026-10-27),

2. 12371470 - Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen (2025-07-29),

3. 12275946 - Compositions and methods for rapid cloning of t-cell receptors (2025-04-14),

4. 11897962 - Anti-GITR antibodies and methods of use thereof (2024-02-13),

5. 11447557 - Antibodies and methods of use thereof (2022-09-20),

6. 11401335 - Anti-GITR antibodies and methods of use thereof (2022-08-02),

7. 11155595 - Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen (2021-10-26),

8. 11020431 - Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors (2021-06-01),

9. 10836830 - Antibodies and methods of use thereof (2020-11-17),

10. 10829559 - Anti-GITR antibodies and methods of use thereof (2020-11-10),

11. 10800849 - Anti-GITR antibodies and methods of use thereof (2020-10-13),

12. 10577426 - Anti-GITR antibodies and methods of use thereof (2020-03-03),

13. 10280226 - Anti-GITR antibodies and methods of use thereof (2019-05-07),

14. 10155818 - Anti-GITR antibodies and methods of use thereof (2018-12-18),

15. 10000546 - Compositions and method for use of recombinant T cell receptors for direct recognition of tumor antigen (2018-06-19),

Title: Innovator Spotlight: Takemasa Tsuji - Pioneering Antibody Therapies

Introduction: Takemasa Tsuji, a prolific inventor based in Williamsville, NY, has made significant contributions to the field of biotechnology with his groundbreaking work in developing novel antibody therapies. With an impressive portfolio of 11 patents, Tsuji's latest inventions focus on antibodies targeting human GITR and OX40 for the treatment of various disorders, including cancer and autoimmune diseases.

Latest Patents: Tsuji's recent patents include "Antibodies and methods of use thereof" and "Anti-GITR antibodies and methods of use thereof." These innovative antibodies are designed to specifically bind to human GITR and OX40, effectively modulating their activity to enhance or inhibit certain physiological responses. The applications of these antibodies extend to the treatment of cancer, infectious diseases, autoimmune, and inflammatory disorders.

Career Highlights: Tsuji has worked with prominent companies in the biotechnology sector, including Agenus Inc. and the prestigious Memorial Sloan Kettering Cancer Center. His expertise and dedication to advancing antibody-based therapies have led to significant advancements in the medical field, offering new hope for patients battling complex diseases.

Collaborations: Throughout his career, Tsuji has collaborated with esteemed professionals in the industry, including Volker Seibert and Olivier Léger. These collaborations have been integral in the development and commercialization of Tsuji's innovative antibody therapies, showcasing the power of teamwork in driving scientific innovation forward.

Conclusion: Takemasa Tsuji's relentless pursuit of excellence in the field of biotechnology has positioned him as a trailblazer in the development of cutting-edge antibody therapies. His patents not only demonstrate his technical prowess but also reflect his commitment to improving healthcare outcomes through groundbreaking innovations. Tsuji's work serves as a testament to the impact that dedicated inventors can have on shaping the future of medicine.

Profile summary based on public USPTO records.